ASX RELEASE MEDICAL MONITORS LIMITED (MDM) ABN 68 009 161 522 Medical Monitors Limited Suite 407 Westfield Eastgardens Eastgardens NSW 2036 Tel (02) 9344 8100 Fax (02) 9344 8200 Web site: www.medmon.com.au 5th October 2004 USA and UK Business Venture to List on AIM The Directors of Medical Monitors Limited (ASX: MDM) have granted a new licensing and distribution agreement to Primedical International Plc. (Primedical), a newly established UK-based investment group. This transaction will replace the recent ‘documentation pending’ announcement with Gallery Investments, Inc., of the USA. Primedical will have the exclusive license and distribution rights for the USA, the UK and European Community (EU) countries, subject to its completion of a further capital raising, for Medical Monitors’ products and services. Primedical will have the financial support of several strategic partners, including a London- based private investment group. Medical Monitors will obtain a major shareholding in Primedical, as well as benefit from an agreed profit margin manufacturing contract and royalty revenue. Primedical intends to access the London Stock Exchange’s Alternative Investment Market (AIM) to provide for further capitalisation, as well as facilitate ‘pre-AIM’ funding of a minimum of £1,000,000 before December 31, 2004. Primedical has engaged one of the UK’s top five biotechnology and corporate brokers in London, who has provided an independent valuation of the business prior to undertaking the AIM listing . Medical Monitors shareholders will be offered a priority placement on the future AIM listing as part of the exclusive relationship with Primedical. Currently, the Directors are in final negotiation for funding of up to $1.0 million, for the company’s Australian operation, for the required manufacturing and technology support of the new venture. About Medical Monitors Medical Monitors’ technology and service model remain superior to the current market offerings in transtelephonic (telephone transfer) cardiac monitoring , and the company will be well placed to take a substantial share of the lucrative international markets. Medical Monitors’ unique transtelephonic (telephone transfer) technologies, which allow doctors to remotely monitor the cardiovascular health of their patients, have already been granted United States Food and Drug Administration (FDA) notification to enable marketing and sales in the USA. For further information, please contact Dr Allan Shell on (02) 9344 8100.
Regards
Commy
MDM Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held